NCT04516915View on ClinicalTrials.gov

IMU-838 and Oseltamivir in the Treatment of COVID-19

PHASE2CompletedINTERVENTIONAL
Enrollment

38

Participants

Timeline

Start Date

June 15, 2020

Primary Completion Date

May 20, 2022

Study Completion Date

September 21, 2022

Conditions
Covid 19
Interventions
DRUG

IMU-838

IMU-838 twice daily at 22.5mg doses for 14 days

DRUG

Oseltamivir

Oseltamivir twice daily at 75mg doses for 14 days

Trial Locations (1)

CV22DX

University Hospital Coventry and Warwickshire NHS Trust, Coventry

Sponsors

Collaborators (2)

Immunic AG
MODEPHARMA
All Listed Sponsors
collaborator

Immunic AG

INDUSTRY

collaborator

University of Warwick

OTHER

collaborator

MODEPHARMA

UNKNOWN

lead

University Hospitals Coventry and Warwickshire NHS Trust

OTHER